# Solve Therapeutics

Source: https://onco.cc/companies/solve-therapeutics/  
OnCo record `solve-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Solve Therapeutics makes antibody-drug conjugates: antibodies that carry a strong cancer drug straight to tumour cells. Its two lead medicines are in early trials in people with advanced solid tumours.

## Summary

Solve Therapeutics, based in San Diego, California, develops antibody-drug conjugates built on CloakLink, which the company describes as a proprietary hydrophilic linker system engineered to mask the hydrophobic properties of ADC payloads. Its two lead programmes, SLV-154 and SLV-324, target membrane receptor proteins on solid tumours that the company has not named publicly, and both are in phase 1 dose-escalation studies (NCT06771219 and NCT07108114). A third registered study, NCT07728942, uses SLR-108, an antibody-radionuclide conjugate, with the unlabelled antibody SLX-1411 for PET imaging in metastatic solid tumours. In November 2025 the company announced an oversubscribed USD 120 million financing led by Yosemite, with Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co. and SymBiosis joining existing investors including Alexandria Venture Investments, General Atlantic and Surveyor Capital. Its first registered cancer trial, NCT06771219, was posted on ClinicalTrials.gov in January 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: San Diego, CA
- Type: biotech
- Website: https://solvetx.com/

## Notes

- Founding year not stated on the company website or in the November 2025 release.
- The antigens targeted by SLV-154 and SLV-324 are not disclosed on the company website.
- Company website, financing release and ClinicalTrials.gov records read on 29 October 2026.

## Sources

- Official website: https://solvetx.com/
- USD 120 million financing release, November 2025: https://solvetx.com/news/solve-therapeutics-raises-120-million-to-develop-best-in-class-adcs-for-solid-tumors/
- ClinicalTrials.gov: phase 1 trial of SLV-154 (NCT06771219): https://clinicaltrials.gov/study/NCT06771219
- ClinicalTrials.gov: phase 1 trial of SLV-324 (NCT07108114): https://clinicaltrials.gov/study/NCT07108114
- ClinicalTrials.gov: phase 1 PET imaging study of SLR-108 (NCT07728942): https://clinicaltrials.gov/study/NCT07728942

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- companies: [Alexandria Venture Investments](https://onco.cc/companies/alexandria-venture-investments/), [Solu Therapeutics](https://onco.cc/companies/solu-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/solve-therapeutics.json